Host: John J. Russell, MD

Guest: Serge A. Jabbour, MD, FACP, FACE

Host Dr. John Russell welcomes Dr. Serge Jabbour, Professor and Endocrinology Division Director at Jefferson University Hospitals in Philadelphia, Pennsylvania. Dr. Jabbour is also the Director of the hospital’s Diabetes Center and Comprehensive Weight Management Program. Dr. Jabbour will review Farxiga® (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Dr. Jabbour will also discuss the efficacy and safety profile of FARXIGA and the clinical development studies. Brought to you by Indication and Limitation of Use For Farxiga® (dapagliflozin) FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Important Safety Information For Farxiga® (dapagliflozin) Contraindications History of a serious hypersensitivity reaction to FARXIGA Severe renal impairment, end stage renal disease, or patients on dialysis Warnings and Precautions Hypotension: FARXIGA causes intravascular volume contraction. Symptomatic hypotension can occur after initiating FARXIGA, particularly in patients with impaired renal function (eGFR <60 mL/min/1.73 m2), elderly patients, or patients on loop diuretics. Before initiating FARXIGA in patients ...

Host: Lee Freedman, MD

Guest: MItchell S. Fineman, MD

Macular Degeneration, also referred to as AMD, is the leading cause of blindness in the developed world, and accounts for more than 50% of all blindness in the United States. In May 2013, the National Eye Institute (NEI) completed the Age-Related Eye Disease Study 2, which tested several changes to the original supplement formulation created as a result of the original AREDS study. Host Dr. Lee Freedman welcomes Dr. Mitchell Fineman, Associate Surgeon at Wills Eye Institute and Associate Professor of Ophthalmology at Jefferson Medical School of Thomas Jefferson University Hospital. Dr. Fineman will discuss AMD, treatment options and the focus on macular vitamin products. View Dr Fineman's webinar.

Host: Shira Johnson, MD

Guest: Javed Butler, MD

Host Dr. Shira Johnson welcomes Dr. Javed Butler, Professor of Medicine, Emory University School of Medicine and Deputy Chief Science Officer, American Heart Association, for an informative discussion on the complexities of acute heart failure. Dr. Butler will be discussing the complex, systemic nature of acute heart failure and review the evidence-based classes of treatment, rationale for use, considerations, and practical application derived from the recent American College of Cardiology Foundation/American Heart Association Guidelines for the Management of Heart Failure. Please join us and listen! 12/13 XAH-1295608

Host: Matt Birnholz, MD

Guest: Eric D. Donnenfeld, MD

Dry eye is the number one reason why patients visit their eye doctor. In the US, an estimated 3.2 million women age 50 and over, and 1.68 million men age 50 and over are affected by dry eye syndrome. Join Dr. Eric Donnenfeld, President of the American Society of Cataract and Refractive Surgeons, as he discusses ocular surface disease and how second generation Omega-3 products can be incorporated into patient management.

Host: Lee Freedman, MD

Guest: S. Gregory Smith, MD

Meibomian gland dysfunction, or MGD, is one of the most challenging issues for eye physicians. Some researchers believe that up to 70 percent of chronic dry eye may actually be due to MGD, not classic dry eye. Join Dr. Gregory Smith, renowned attending surgeon at Wills Eye Hospital in Philadelphia, as he discusses MGD and his research that demonstrates how Omega-3 in the re-esterified triglyceride form can combat this medical issue.

Host: John J. Russell, MD

Guest: Sol Epstein, MD, FRCP, FACP

Bisphosphonates were the first class of drugs to be approved for the treatment of osteoporosis, and they remain the foundation of treatment to this day. What is it about this class that makes it so efficacious—and what are some of the pitfalls? Host Dr. John Russell welcomes Sol Epstein, MD, FRCP, FACP, professor of medicine and geriatrics at Mt. Sinai School of Medicine in New York, and adjunct professor of medicine at the University of Pennsylvania. Dr. Epstein is currently a paid consultant to Mission Pharmacal Company.

Host: John J. Russell, MD

Guest: Sol Epstein, MD, FRCP, FACP

Osteoporotic fractures occur with great frequency and exact a heavy toll on the individual as well as the community. When a woman is diagnosed with osteoporosis, what are the specific management and treatment goals? Host Dr. John Russell welcomes Sol Epstein, MD, FRCP, FACP, professor of medicine and geriatrics at Mt. Sinai School of Medicine in New York, and adjunct professor of medicine at the University of Pennsylvania. Dr. Epstein is currently a paid consultant to Mission Pharmacal Company.

Host: John J. Russell, MD

Guest: Sol Epstein, MD, FRCP, FACP

Osteoporotic fractures are among the most prevalent postmenopausal health conditions. In the US alone, more than 1.5 million fractures, including 700,000 vertebral and 300,000 hip fractures, occur in men and women every year. Host Dr. John Russell welcomes Dr. Sol Epstein, an osteoporosis expert who will discuss strategies for dealing with this major public health issue. Dr. Epstein is professor of medicine and geriatrics at Mt. Sinai School of Medicine in New York, and adjunct professor of medicine at the University of Pennsylvania. Dr. Epstein is currently a paid consultant to Mission Pharmacal Company.